Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO)

Perfusion (United Kingdom)

Volumn 31, Issue 2, 2016, Pages 95-102

  Stocker, Christian F ^a   Horton, Stephen B ^b  

^a LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

anticoagulation; complications; ECLS; ECMO; neonatal; paediatric

Indexed keywords

AMINOCAPROIC ACID; HEPARIN; ILOPROST; ANTICOAGULANT AGENT;

ACTIVATED CLOTTING TIME; ANTICOAGULANT THERAPY; BLOOD CLOTTING PARAMETERS; CENTRIFUGAL PUMP; COMORBIDITY; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; HUMAN; MONITOR; MULTIPLE ORGAN FAILURE; OXYGENATOR; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTHROMBIN TIME; REGISTER; REVIEW; THROMBOELASTOGRAPHY; VENTRICULAR ASSIST DEVICE; ADOLESCENT; ADVERSE EFFECTS; CHILD; HEMOSTASIS; INFANT; NEWBORN; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; HEMOSTASIS; HUMANS; INFANT; INFANT, NEWBORN;

EID: 84958982817     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659115590626     Document Type: Review

References (35)

1. Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P,. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14: e77-84.
2. Newall F, Ignjatovic V, Johnston L, et al. Clinical use of unfractionated heparin therapy in children: time for change? Br J Haematol 2010; 150: 674-678.
3. (ELSO) ELSO. ELSO Registry Report: International Summary January 2013. 2013.
4. Lawson S, Ellis C, Butler K, McRobb C, Mejak B,. Neonatal extracorporeal membrane oxygenation devices, techniques and team roles: 2011 survey results of the United States' Extracorporeal Life Support Organization centers. J Extra Corpor Technol 2011; 43: 236-244.
5. Lequier LL, Massicotte P,. Anticoagulation and bleeding during ECLS. In: Annich GM, Lynch WR, MacLaren G, Wilson JM, Bartlett RH, (eds). ECMO: Extracorporeal Life Support in Critical Care. Ann Arbor: ELSO; 2012: pp. 157-170.
6. Marcum JA,. The origin of the dispute over the discovery of heparin. J Hist Med Allied Sci 2000; 1: 37-66.
7. Best CH,. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19: 79-86.
8. Becker RC,. Cell-based models of coagulation: a paradigm in evolution. J Thromb Thrombolys 2005; 20: 65-68.
9. Annich GM, Massicotte MP, Lequier LL,. Blood biomaterial surface interaction during ECLS. In: Annich GM, Lynch WR, MacLaren G, Wilson JM, Bartlett RH, (eds). ECMO: Extracorporeal Cardiopulmonary Support in Critical Care. Ann Arbor: ELSO; 2012: pp. 75-86.
10. Hoffman M, Monroe DM 3rd,. A cell-based model of hemostasis. Thromb Haemostas 2001; 85: 958-965.
11. Zabrocki LA, Brogan TV, Statler KD, Poss WB, Rollins MD, Bratton SL,. Extracorporeal membrane oxygenation for pediatric respiratory failure: survival and predictors of mortality. Crit Care Med 2011; 39: 364-370.
12. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467.
13. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S-159S.
14. Ignjatovic V, Straka E, Summerhayes R, Monagle P,. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemostas 2010; 8: 1290-1294.
15. Ignjatovic V, Furmedge J, Newall F, et al. Age-related differences in heparin response. Thromb Res 2006; 118: 741-745.
16. Baird CW, Zurakowski D, Robinson B, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83: 912-919; discussion 19-20.
17. Miller BE, Bailey JM, Mancuso TJ, et al. Functional maturity of the coagulation system in children: an evaluation using thrombelastography. Anesth Analg 1997; 84: 745-748.
18. Oliver WC,. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13: 154-175.
19. Hirsh J. Heparin., N Eng J Med 1991; 324: 1565-1574.
20. Basu D, Gallus A, Hirsh J, Cade J,. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Eng J Med 1972; 287: 324-327.
21. Zucker S, Cathey MH,. Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin. J Lab Clin Med 1969; 73: 320-326.
22. Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD,. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Ped Crit Care Med 2012; 13: e363-371.
23. Liveris A, Bello RA, Friedmann P, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Ped Crit Care Med 2014; 15: e72-79.
24. Alexander DC, Butt WW, Best JD, Donath SM, Monagle PT, Shekerdemian LS,. Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. Thromb Res 2010; 125: 387-392.
25. Annich G, Adachi I,. Anticoagulation for pediatric mechanical circulatory support. Ped Crit Care Med 2013; 14: S37-42.
26. Reynolds MM, Annich GM,. The artificial endothelium. Organogenesis 2011; 7: 42-49.
27. Ranucci M, Ballotta A, Kandil H, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011; 15: R275.
28. Niebler RA, Christensen M, Berens R, Wellner H, Mikhailov T, Tweddell JS,. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 2011; 35: 1024-1028.
29. Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C,. Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J 2006; 52: 513-516.
30. Downard CD, Betit P, Chang RW, Garza JJ, Arnold JH, Wilson JM,. Impact of AMICAR on hemorrhagic complications of ECMO: a ten-year review. J Ped Surg 2003; 38: 1212-1216.
31. Chung A, Wildhirt SM, Wang S, Koshal A, Radomski MW,. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study. J Thorac Cardiovasc Surg 2005; 129: 782-790.
32. Chan KL, Summerhayes RG, Ignjatovic V, Horton SB, Monagle PT,. Reference values for kaolin-activated thromboelastography in healthy children. Anesth Analg 2007; 105: 1610-1613.
33. Baldwin JT, Borovetz HS, Duncan BW, Gartner MJ, Jarvik RK, Weiss WJ,. The national heart, lung, and blood institute pediatric circulatory support program: a summary of the 5-year experience. Circulation 2011; 123: 1233-1240.
34. Vandiver JW, Vondracek TG,. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32: 546-558.
35. Nguyen T, Musick M, Teruya J,. Anticoagulation monitoring during extracorporeal membrane oxygenation: is anti-factor Xa assay (heparin level) a better test? Ped Crit Care Med 2014; 15: 178-179.